Osimertinib as a third-generation EGFR TKI in non-small cell lung cancer: selective targeting of T790M mutation and clinical advantages
DOI:
https://doi.org/10.58445/rars.2916Keywords:
Epidermal Growth Factor Receptor (EGFR), Tyrosine Kinase Inhibitor (TKI), Non-Small Cell Lung Cancer (NSCLC), T790M mutation, OsimertinibAbstract
Non-small cell lung cancer is the most common type of lung cancer, accounting for around 85% of all cases (Testa et al.). Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that harbors EGFR mutations, such as the T790M mutation. T790M mutation, which is the substitution of threonine with methionine at amino acid position 790 in the EGFR protein due to a mutation in exon 20, is the most common mechanism that resists first- or second-generation TKI drugs. Approximately 50%-60% of patients receiving early-generation TKIs develop resistance (Fu et al.). Preclinical studies have shown that Osimertinib may be a favorable treatment option for patients who have developed resistance to first- or second-generation TKI drugs. This paper reviews the action and clinical advantages of third-generation TKI Osimertinib.
References
Castañeda-González, Juan Pablo, et al. “Multiple Mutations in the EGFR Gene in Lung Cancer: A Systematic Review.” Translational Lung Cancer Research, vol. 0, no. 0, Jan. 2021, https://doi.org/10.21037/tlcr-22-235. Accessed 25 Sept. 2022.
Chmielecki, Juliann, et al. “Analysis of Acquired Resistance Mechanisms to Osimertinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer from the AURA3 Trial.” Nature Communications, vol. 14, no. 1, 27 Feb. 2023, https://doi.org/10.1038/s41467-023-35962-x.
Colclough, Nicola, et al. Preclinical Comparison of the Blood–Brain Barrier Permeability of Osimertinib with Other EGFR TKIs. Vol. 27, no. 1, 1 Jan. 2021, pp. 189–201, https://doi.org/10.1158/1078-0432.ccr-19-1871.
“Beyond Epidermal Growth Factor Receptor: MET Amplification as a General Resistance Driver to Targeted Therapy in Oncogene-Driven Non-Small-Cell Lung Cancer.” ESMO Open, vol. 6, no. 6, Dec. 2021, p. 100319, https://doi.org/10.1016/j.esmoop.2021.100319.
Cross, Darren A E, et al. “AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer.” Cancer Discovery, vol. 4, no. 9, 2014, pp. 1046–61, www.ncbi.nlm.nih.gov/pubmed/24893891/, https://doi.org/10.1158/2159-8290.CD-14-0337.
Fu, Kai, et al. “Therapeutic Strategies for EGFR-Mutated Non-Small Cell Lung Cancer Patients with Osimertinib Resistance.” Journal of Hematology & Oncology, vol. 15, no. 1, 8 Dec. 2022, jhoonline.biomedcentral.com/articles/10.1186/s13045-022-01391-4, https://doi.org/10.1186/s13045-022-01391-4.
Koulouris, Andreas, et al. “Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies.” Cancers, vol. 14, no. 14, 8 July 2022, p. 3337, pubmed.ncbi.nlm.nih.gov/35884398/, https://doi.org/10.3390/cancers14143337. Accessed 24 Oct. 2022.
Loryan, Irena, et al. “Unbound Brain-To-Plasma Partition Coefficient, Kp,Uu,Brain—a Game Changing Parameter for CNS Drug Discovery and Development.” Pharmaceutical Research, vol. 39, no. 7, 11 Apr. 2022, pp. 1321–1341, https://doi.org/10.1007/s11095-022-03246-6. Accessed 6 Sept. 2023.
Odogwu, Lauretta, et al. “FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.” The Oncologist, vol. 23, no. 3, 1 Mar. 2018, pp. 353–359, pubmed.ncbi.nlm.nih.gov/29242281/, https://doi.org/10.1634/theoncologist.2017-0425. Accessed 3 Aug. 2021.
Ou, Xuejin, et al. “Mechanisms of Resistance to Tyrosine Kinase Inhibitor-Targeted Therapy and Overcoming Strategies.” MedComm, vol. 5, no. 9, Winter 2024, p. e694, pubmed.ncbi.nlm.nih.gov/39184861/, https://doi.org/10.1002/mco2.694.
Peng, Mu-Han, et al. “Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation.” Cancers, vol. 16, no. 24, 14 Dec. 2024, pp. 4174–4174, www.mdpi.com/2072-6694/16/24/4174, https://doi.org/10.3390/cancers16244174. Accessed 17 Dec. 2024.
Testa, Ugo, et al. “Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.” Cancers, vol. 10, no. 8, 27 July 2018, p. 248, https://doi.org/10.3390/cancers10080248.
“The Cancer Therapy Arms Race | Bio-Rad.” Bio-Rad, 2019, www.bio-rad-antibodies.com/blog/cancer-therapy-arms-race.html. Accessed 5 July 2025.
Wang, Chunsheng, et al. “Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis.” Frontiers in Oncology, vol. 11, 2 Mar. 2021, https://doi.org/10.3389/fonc.2021.600844. Accessed 16 Apr. 2022.
Zhang, Die, et al. “Fourth-Generation EGFR-TKI to Overcome C797S Mutation: Past, Present, and Future.” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 40, no. 1, 2 Apr. 2025, https://doi.org/10.1080/14756366.2025.2481392. Accessed 6 Apr. 2025.
Downloads
Posted
Categories
License
Copyright (c) 2025 Siri Srivatsa, Lalita Limaye
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.